Solid performance across all businesses

“

All businesses continued their solid performance and contributed to the growth.

Published on 23 April 2026

"In January–March 2026, our net sales increased by 17.8 percent to EUR 417.7 (354.6) million and operating profit increased by 47.3 percent to EUR 114.8 (77.9) million. All businesses continued their solid performance and contributed to the growth.

Nubeqa® maintained its strong growth trajectory with both royalties and product sales significantly increasing from the comparative period. Growth of the Branded Products business division was again driven by the Easyhaler® product portfolio. We continued to experience the product mix shift from mono-therapy products to budesonide-formoterol combination product due to changes in treatment practices. The good growth momentum of the women's health therapy area also continued.

The performance of the Generics and Consumer Health business division was quite stable during the quarter, with consumer health growing faster than the generics. The Animal Health business division and Fermion also performed in line with the expectations.

During Q1, we continued the work to advance our clinical development pipeline. Orion's ongoing clinical trials and preparations to initiate further clinical phase 2 trials with our investigational TEAD inhibitor ODM-212 progressed as planned, and we were able to start the TEADCO phase 1b/2 trial which evaluates ODM-212 in combination with standard of care treatments in select solid tumours after the reporting period in April. Another important milestone for ODM-212 was the reception of orphan drug designation in mesothelioma by FDA.

As part of the execution of our long-term growth strategy, we have strengthened our executive team with the appointment of Berkeley Vincent as Executive Vice President of Innovative Medicines. In this role, Berkeley will lead the definition and execution of global commercialization strategies for our Innovative Medicines portfolio. Following this appointment, Outi Vaarala — who previously held the EVP Innovative Medicines role alongside her other responsibilities — will be able to fully focus on leading Orion’s R&D organization.

To summarise, Orion's Q1 was steady with strong execution across all areas. Due to the solid start of the year, we have specified our outlook for 2026 by narrowing both the net sales and operating profit ranges from the lower end. Q1 laid a good foundation for the year."